These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31560935)

  • 1. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
    Tam BY; Chiu K; Chung H; Bossard C; Nguyen JD; Creger E; Eastman BW; Mak CC; Ibanez M; Ghias A; Cahiwat J; Do L; Cho S; Nguyen J; Deshmukh V; Stewart J; Chen CW; Barroga C; Dellamary L; Kc SK; Phalen TJ; Hood J; Cha S; Yazici Y
    Cancer Lett; 2020 Mar; 473():186-197. PubMed ID: 31560935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
    Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
    Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential.
    Martín Moyano P; Němec V; Paruch K
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
    Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
    PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNIK inhibition abrogates colorectal cancer stemness.
    Masuda M; Uno Y; Ohbayashi N; Ohata H; Mimata A; Kukimoto-Niino M; Moriyama H; Kashimoto S; Inoue T; Goto N; Okamoto K; Shirouzu M; Sawa M; Yamada T
    Nat Commun; 2016 Aug; 7():12586. PubMed ID: 27562646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
    Murai A; Ebara S; Sasaki S; Ohashi T; Miyazaki T; Nomura T; Araki S
    PLoS One; 2020; 15(10):e0240718. PubMed ID: 33064779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raddeanin A inhibits growth and induces apoptosis in human colorectal cancer through downregulating the Wnt/β-catenin and NF-κB signaling pathway.
    Wang Y; Bao X; Zhao A; Zhang J; Zhang M; Zhang Q; Ma B
    Life Sci; 2018 Aug; 207():532-549. PubMed ID: 29972765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of influenza A virus mRNA splicing by CLK1.
    Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
    Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in
    Corr BR; Moroney MR; Woodruff E; Watson ZL; Jordan KR; Danhorn T; Bailey C; Wolsky RJ; Bitler BG
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.
    Lee Y; Jung JI; Park KY; Kim SA; Kim J
    Oncotarget; 2017 Jun; 8(25):41091-41101. PubMed ID: 28467797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisleuconothine A, a bisindole alkaloid, inhibits colorectal cancer cell in vitro and in vivo targeting Wnt signaling.
    Kong LM; Feng T; Wang YY; Li XY; Ye ZN; An T; Qing C; Luo XD; Li Y
    Oncotarget; 2016 Mar; 7(9):10203-14. PubMed ID: 26862734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
    Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
    Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
    Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
    Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
    Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
    EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.
    Jiang K; Patel NA; Watson JE; Apostolatos H; Kleiman E; Hanson O; Hagiwara M; Cooper DR
    Endocrinology; 2009 May; 150(5):2087-97. PubMed ID: 19116344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
    Zhan T; Ambrosi G; Wandmacher AM; Rauscher B; Betge J; Rindtorff N; Häussler RS; Hinsenkamp I; Bamberg L; Hessling B; Müller-Decker K; Erdmann G; Burgermeister E; Ebert MP; Boutros M
    Nat Commun; 2019 May; 10(1):2197. PubMed ID: 31097693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
    Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
    BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
    Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
    Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway.
    Thorsen K; Mansilla F; Schepeler T; Øster B; Rasmussen MH; Dyrskjøt L; Karni R; Akerman M; Krainer AR; Laurberg S; Andersen CL; Ørntoft TF
    Mol Cell Proteomics; 2011 Jan; 10(1):M110.002998. PubMed ID: 20938052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.